Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Brian A Jonas
City of Hope Comprehensive Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Los Angeles General Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Usc Norris Oncology/hematology-Newport Beach
Newport Beach, California, United States
- Keck Medical Center of Usc Pasadena
Pasadena, California, United States
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- Um Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Mount Sinai Hospital
New York, New York, United States
- University of Cincinnati Cancer Center-Uc Medical Center
Cincinnati, Ohio, United States
- University of Cincinnati Cancer Center-West Chester
West Chester, Ohio, United States
- University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 May 2020
- Primary completion
- 30 Jun 2027
- Completion
- 30 Jun 2027
- Last update posted
- 11 Jun 2026
- Registered enrollment
- 48
- Registry id
- NCT03983824
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.